Single Intracoronary Injection of Encapsulated Antagomir-92a Promotes Angiogenesis and Prevents Adverse Infarct Remodeling

Neus Bellera, MD, PhD; Ignasi Barba, PhD; Antonio Rodriguez-Sinovas, DVM, PhD; Eulalia Ferret, PhD; Miguel Angel Asín, PhD; Mª Teresa Gonzalez-Alujas, MD, PhD; Jordi Pérez-Rodon, MD; Marielle Esteves, DVM; Carla Fonseca, DVM; Nuria Toran, MD, PhD; Bruno García del Blanco, MD; Amadeo Pérez, PhD; David García-Dorado, MD, PhD; FESC, FACC, FAHA

Background—Small and large preclinical animal models have shown that antagomir-92a-based therapy reduces early postischemic loss of function, but its effect on postinfarction remodeling is not known. In addition, the reported remote miR-92a inhibition in noncardiac organs prevents the translation of nonvectorized miR-targeted therapy to the clinical setting. We investigated whether a single intracoronary administration of antagomir-92a encapsulated in microspheres could prevent deleterious remodeling of myocardium 1 month after acute myocardial infarction

Author: Should “acute” be added before “myocardial infarction” (since abbreviation is AMI)? Also check at first mention in main text (AMI) without adverse effects.

Methods and Results—In a percutaneous pig model of reperfused AMI, a single intracoronary administration of antagomir-92a encapsulated in specific microspheres (9 μm poly-ε-lactide-co-glycolide [PLGA]) inhibited miR-92a in a local, selective, and sustained manner (n=3 pigs euthanized 1, 3, and 10 days after treatment; 8×, 2×, and 5×-fold inhibition at 1, 3, and 10 days). Downregulation of miR-92a resulted in significant vessel growth (n=27 adult minipigs randomly allocated to blind receive encapsulated antagomir-92a, encapsulated placebo, or saline [n=8, 9, 9]; P=0.001), reduced regional wall-motion dysfunction (P=0.03), and prevented adverse remodeling in the infarct area 1 month after injury (P=0.03). Intracoronary injection of microspheres had no significant adverse effect in downstream myocardium in healthy pigs (n=2), and fluorescein isothiocyanate albumin-PLGA microspheres were not found in myocardium outside the left anterior descending coronary artery territory (n=4) or in other organs (n=2).

Conclusions—Early single intracoronary administration of encapsulated antagomir-92a in an adult pig model of reperfused AMI prevents left ventricular remodeling with no local or distant adverse effects, emerging as a promising therapeutic approach to translate to patients who suffer a large AMI.

(J Am Heart Assoc. 2014;3:e000946 doi: 10.1161/JAHA.114.000946)

Key Words: Angiogenesis • antagomir • heart failure • microRNA • myocardial infarction • remodeling

Implementation of prompt reperfusion does not prevent the occurrence of adverse ventricular remodeling in a large number of patients with acute myocardial infarction (AMI), especially in those with extensive anterior wall infarct. Reducing the infarct extension and fibrous replacement by promoting therapeutic sprouting and proliferation of vessels within the infarct scar would appear to be a sensible target to ameliorate myocardial remodeling. The postnatal type of neoangiogenesis is an integral component of the remodeling process, but the rate of capillary formation is too slow to salvage cardiomyocytes. Clinical studies with isolated proangiogenic factors, such as vascular endothelial growth factor gene therapy, have shown a lack of improvement of perfusion of ischemic myocardium in patients with advanced coronary disease. Granulocyte colony-stimulating factor and granulocyte colony-stimulating factor–stimulated cells have also been proposed to repopulate and increase vascular-bed angiogenesis after AMI, but the improvements of left ventricular ejection fraction and end-systolic volumes have not been significantly better than control at 2 years.

MicroRNAs (miR) have emerged as crucial regulators of vasculogenesis, and studies targeting these small
22-nucleotide RNAs are providing more encouraging results in ischemic heart disease.\textsuperscript{11,12} Inhibition of miR-92a, an anti-angiogenic miR by repeated intravenous injections of antagonim-92a induces angiogenesis and improves recovery of ventricular function in a mouse model of AMI.\textsuperscript{13} In addition, cardioprotection against ischemia/reperfusion has been observed in a pig model of AMI regionally treated with antagonim-92a.\textsuperscript{14} However, remote miR-92a inhibition in noncardiac organs has been reported for both systemic and regional delivery.\textsuperscript{14} Therefore, the translation of miR-targeted modulation therapy to the clinical setting is limited by the potential for unwanted effects in distant regions due to the cellular ubiquity of miR-92a.\textsuperscript{15–17}

Our goal was to test the efficacy and safety of a new therapy to prevent postinfarction myocardial remodeling based on the intracoronary injection of antagonim-92a encapsulated in specifically designed, bioabsorbable, and biocompatible microspheres (ME). We found that a single intracoronary administration of those ME at the time of reperfusion inhibits miR-92a locally for at least 10 days after AMI, inducing vessel growth and preventing the development of adverse remodeling. These results identify local and sustained release of antagonim-92a encapsulated in ME as a promising, new approach to treat patients with AMI at risk of developing adverse remodeling.

### Methods

#### Minipigs

Adult 12-month-old male minipigs (mean body weight 26±5 kg) were purchased from Ellegaard Göttingen Minipigs\textsuperscript{®} A/S, Denmark.

#### Preparation of ME

ME loaded with antagonim-92a were prepared by an emulsion/solvent evaporation method using a 50:50 poly-\(\alpha\)-lactide-co-glycolide (PLGA) copolymer (intrinsic viscosity 0.2 dL/g). A solution of antagonim-92a was emulsified in a PLGA organic solution. The obtained emulsion was in turn incorporated in a dispersing aqueous phase and homogenized to obtain the desired particle size. Finally, after the solvent evaporation, the obtained ME were freeze-dried. Placebo ME and ME with fluorescein isothiocyanate albumin were prepared following the same methodology. Size and composition of PLGA were selected to hold out the degradation process for a period of 21 to 30 days. In addition, the released antagonim-92a was a locked nucleic acid specifically designed by Exiqon to extend its stability in blood to this period.

### Animal Experiments

All experiments were carried out in strict accordance with the protocols approved by the Animal Care Committee, Institut de Recerca (N. Registro: 19/10 CEEA-Departament de Medi Ambient i Habitatge: B9900062) and the Guide for the Care and Use of Laboratory Animals published by Directive 2010/63/EU of the European Parliament and of the Council of September 22, 2010 on the protection of animals used for scientific purposes.

#### Induction of Reperfused AMI

After IM sedation by 4 mg/kg tiletamina-zolazepam (Zoletil\textsuperscript{®})+2 mg/kg xilazine (Xilagescic\textsuperscript{®} 20%) and anesthesia by intravenous propofol (Propofol-lipuro\textsuperscript{®} 1% 10 mg/mL) and fentanyl (Fentanest\textsuperscript{®} 0.15 mg/3 mL) (1.5 to 2.5 mg/kg bolus+infusion: 11 mg/kg per hour and 5 µg/kg bolus+infusion: 3 to 6 µg/kg per hour, respectively), minipigs were intubated and monitored. Vital parameters and electrocardiographic curves were recorded using Collect 55 software (GE Healthcare, Belford, UK). The femoral artery and vein were cannulated by placing a 7F and 12F sheath, respectively. Heparin (300 IU/kg) and lysine acetylsalicylate (450 mg) were administered intravenously. Coronary angiography was performed using iopamiro contrast (lopamiro\textsuperscript{®} 370). The left main coronary artery was selectively cannulated with an anterior mammary internal guiding 5F catheter. A BMW Universal 0.014" wire was placed in the distal left anterior descending coronary artery (LAD) and a coaxial balloon (2.5/12 mm) was advanced and positioned in the middle section, just after the first diagonal branch. The balloon was inflated until occlusion of the vessel was confirmed by simultaneous antegrade contrast injection. AMI was confirmed by evidence of ST-segment elevation, an increase in cardiac enzyme levels, and regional wall-motion dysfunction observed by intravascular echocardiography (IVE). The durations of ischemia of 49 and 60 minutes were defined in a previous study specifically designed to establish the relationship between duration of transient coronary occlusion and infarct size in the pig model,\textsuperscript{18} and have been used by our group in many subsequent studies. In the present study, we used ischemic periods of 49 minutes expected to result in infarct size of 50% of the area at risk, or 60 minutes, expected to result in nearly transmural infarcts and more severe remodeling, but also in higher mortality. Twenty-seven minipigs were allocated to the postinfarction remodeling study. Animals were randomly allocated to the 3 treatment groups according to a randomization list generated by the Department of Statistics of Vall d’Hebron Research Institute. All investigators were blind to the randomization codes.
One animal could not complete the coronary occlusion protocol. Nine animals were allocated to the different treatments in the 49-minute protocol (saline n=3, placebo ME n=3, antagonim-92a ME n=3): 1 in the saline group died during the surgical procedure. The remaining 17 animals were randomly allocated to saline n=6, placebo ME n=6, and antagonim-92a ME n=5 in the 60-minute protocol. Three of these animals died during the surgical procedure (1 saline, 2 placebo ME) and 2 additional animals died during the subsequent 30 days (1 saline, 1 antagonim-92a ME). There were, thus, 20 valid experiments: 8 from the 49-minute protocol (saline n=2, placebo ME n=3, antagonim-92a n=3), and 12 from the 60-minute protocol (saline n=4, placebo ME n=4, antagonim-92a ME n=4).

To determine the arrhythmogenic potential of encapsulated antagonim-92a, all arrhythmic events during the procedures were recorded and analyzed by Collect 5S software (GE Healthcare, Belford, UK).

**Examination of ME Biodistribution**

To examine the biodistribution of ME in vivo, we induced an AMI by percutaneous balloon occlusion of the middle LAD coronary artery for a period of 49 minutes (n=4). Five minutes after reperfusion, 30 mg of fluorescein isothiocyanate albumin–PLGA ME dissolved in 2 injections of 5 mL of 0.15 mol/L PBS containing 0.01% Tween 80 (final ME concentration: 3 mg/mL) were administered by the intracoronary route through the lumen of the deflated coaxial balloon placed in the same position. Ten minutes later, pigs were euthanized and 5 replicate samples from the anterior myocardium and from the posterior control zone were obtained.

To rule out systemic biodistribution, we examined the presence of ME in different organs (n=2). Ischemic and control myocardial tissue and 5 replicate samples from lung, spleen, and liver were obtained after induction.
of AMI and intracoronary administration of ME, according to the methodology described above. All samples were stored at −80°C until visualization by optical microscopy.

**Figure 3.** Detection of fluorescein isothiocyanate albumin-PLGA microspheres in myocardial samples from pigs exposed to 49 minutes of ischemia and treated at 5 minutes of reperfusion with 2 intracoronary injections containing 30 mg of labeled microspheres. Representative images of control and ischemic ventricular myocardium sections visualized by fluorescence optical microscopy (blue light with wavelength of 495 nm). Microspheres were present in the ischemic zone but not in the control zone. Scale bar: 50 μm. n=4. PLGA indicates poly-D,L-lactide-co-glycolide.

**Treatment Administration**

Two silver-covered injections of 5 and 8.7 mL with 3 mg/mL of ME containing antagomir-92a (3 mg: 0.1 mg/kg body

**Figure 4.** Detection of fluorescein isothiocyanate albumin-PLGA microspheres in heart and in extracardiac tissues. Five replicate heart, lung, liver, and spleen samples were obtained with a 2-mm punch and frozen at −80°C. Afterward, 5 μm of each tissue was placed on a slide and visualized with optical microscopy with fluorescence (blue light with wavelength of 495 nm). The image shows fluorescence exclusively detected in capillaries of infarcted myocardial wall. Scale bar: 50 μm. n=2. PLGA indicates poly-D,L-lactide-co-glycolide.
weight), ME containing placebo, or saline were intracoronarily administered through the coaxial lumen of the deflated balloon, 5 minutes after reperfusion. ME were resuspended in 0.15 mol/L PBS with 0.01% Tween80 immediately before administration. Each injection was followed by 5 mL of saline.

**Intravascular Echocardiographic Assessment**

IVE was performed for functional analysis using a Vivid Q ultrasound imaging device (GE Healthcare, Belford, UK). An AcuNav™ 10 F ultrasound catheter (Siemens, Malvern) was
advanced through the venous 12 F sheath and positioned in the apex of the right ventricle. Two-dimensional images showing the apex of the left ventricle (LV), the septum, and the mitral valve were obtained and visualized throughout the procedure. Loops at baseline, during AMI induction, immediately at the end of ischemia, and during reperfusion were recorded. One month later, the same methodology was applied and the presence of septoapical dyskinesia was evaluated. Loops of each animal were recorded on a digital versatile disc and analyzed by an echocardiographer blind to the allocated treatment. All echocardiographic measurements were averaged over 5 consecutive cardiac cycles.

**Implantable Loop Recorder Insertion**

After treatment administration and with the animals under general anesthesia, an implantable loop recorder (Reveal DX and Reveal XT in 8 and 2 pigs, respectively; Medtronic Inc, Minneapolis, MN) was inserted subcutaneously in the left parasternal area. The devices were just after the implantation to ascertain a correct signal detection and 1 month after treatment to check for cardiac arrhythmias.

**Housing**

Animals were housed during the 1 month following AMI with a temperature of 20 to 22°C and relative humidity of 40% to 70%.

---

**Figure 6.** Second intracoronary injection of 15 mg of microspheres: effects in coronary flow, hemodynamics, and contractility. The same parameters described in Figure 5 were obtained during the second injection of 15 mg of fluorescein isothiocyanate albumin–PLGA microspheres. The graphics show minimal and transient changes in contractility returning to baseline evaluated with piezoelectric crystals and discarding ischemic injury by the microspheres. Isolated premature ventricular complexes were induced during the injections and those explain the momentary reduction in heart rate (HR) with simultaneous oscillations in left ventricular pressures. Afterward, the animal was euthanized and the presence of those microspheres in myocardial tissue was confirmed by optical fluorescence microscopy. n=2. Ao pressure indicates aortic pressure; C, control pair of crystals; EDL, end-diastole length; ESL, end-systole length; I, ischemic pair of crystals; LV pressure, left ventricle pressure and its derivative LV dP/dT, left ventricular dP/dT; LVEDP, left ventricular end-diastolic pressure; LVE SP, left ventricular end-systolic pressure; Max L, maximum length; Min L, minimum length; SS, systolic shortening=(EDL–ESL)/EDL; PLGA, poly-o-,lactide-co-glycolide.
The light–dark cycle was 12 hours. Animals were fed diet SMP (Minipigs expanded)—Code 801586 (DIETEX France, Argen-
teuil). The first day after AMI, oxygen and a fentanyl patch were
provided. Acetylsalicylic acid (100 mg) was administered daily.
Minipigs were visited daily to measure weight, heart rate,
oxygen saturation, and temperature and to examine the femoral
and Reveal/C226 area wound. No local bleeding was observed. Local
infection of the implantable loop recorder in 1 animal was
resolved with antibiotics and surgical drainage.

Catheterization and Thoracotomy: Microcirculatory Resistances Calculation

One month after AMI, animals were anesthetized, intubated,
and monitored as described above. Femoral artery and vein
were again punctured and 7 and 12 F sheaths were placed,
respectively. Heparin (300 IU/kg) was administered intra-
venously. After IVE assessment, coronary angiography was
repeated as described. LAD characteristics and flow were
determined. A pressure wire (Primewire, Volcano Thera-
pic Inc, Zaventem, Belgium) was advanced to the apical
segment of the LAD and the distal pressure (Pd, mm Hg)
was measured. Thereafter, thoracotomy and pericardiectomy
were performed and the LAD was dissected to insert a
flow sensor in the middle segment of LAD (Flowmeter
T206, Transonic Systems Inc, NY). Coronary flow (Qc, mL/
min) was measured. Baseline microcirculatory resistance
(baseline MR) was calculated (Pd/Qc). Thereafter, an
intravenous infusion of adenosine (140 μg/kg per minute)
through the femoral vein 12F sheath was started and

Figure 7. Evaluation of potential myocardial toxicity. An experiment was conducted to analyze whether the microspheres caused damage to the cardiac muscle or the coronary flow rate. Intracoronary injections (I) of 10 mL saline (S1)+6 I×15 mg microspheres+S2+20 mL S3+10 min ischemia+S4+13 min reperfusion. The separation between the ischemic pair of crystals becomes increasingly larger and longer but returns to the baseline after a few minutes. No irreversible ischemic damage was observed with a total dose of 120 mg of microspheres administered into the LAD through a coaxial balloon placed in the middle segment. n=1. Ao pressure indicates aortic pressure; C, control pair of crystals; EDL, end-diastole length; ESL, end-systole length; HR, heart rate; I, ischemic pair of crystals; LAD, left anterior descending coronary artery; LV pressure, left ventricle pressure and its derivative LV dP/dT, left ventricular dP/dT; LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure; Max L, maximum length; Min L, minimum length; SS, systolic shortening.
Maintained for 10 minutes to induce hyperemia (hyp). At 10 minutes, true microcirculatory resistance was also calculated measuring the same parameters during maximal hyperemia (Pd_{hyp}/Qc_{hyp}).

Sacriﬁce and Necropsy Study

Minipigs were euthanized 33±4 days after AMI with a thiopental (Tiobarbital⁶) overdose. Just before sacrifice, 2 samples each of lung, liver, kidney, and spleen were obtained and frozen in liquid nitrogen and stored at −80°C. The hearts were then removed and ﬁxed in 10% formalin under pressure by ﬁlling the ventricular cavities with gauzes to maintain LV diastolic geometry. A necropsy study was performed in all animals, looking for pathological changes in any of the major organs and focusing attention on vascular neoformations.

Cardiac Magnetic Resonance Imaging

Formalin-ﬁxed hearts were analyzed by cardiac magnetic resonance imaging at 1.5 Tesla (GE Healthcare, Belford, UK) using a T2W pulse sequence. Remodeling parameters (maximum and minimum infarcted wall thickness [T_{max} and T_{min} infracted wall, respectively]; noninfarcted wall thickness was measured just beside the insertion of posterior papillary muscle [T_{normal} posterior wall]; percentage of minimum and maximum thinning were calculated as [100−(T_{max}/T_{normal} posterior×100)] and [100−(T_{min}/T_{normal} posterior×100)], respectively; maximum diameter between remodeled and contralateral normal wall, passing through the cavity center [LV D_{a}]; maximum diameter between normal ventricular walls, perpendicular to LV D_{a} and passing nearest the center of the ventricular cavity [LV D_{v}]; sphericity index [LV D_{a}/D_{v}] were measured by 2 observers blinded to the treatment allocation.

Figure 8. Evaluation of therapeutic safety range of dose. An experiment was conducted to investigate the therapeutic safety range of dose. Intracoronary injections (I) of 10 mL saline+6 I×15 mg microspheres+2 I×30 mg microspheres+4 I×15 mg microspheres+1 I×30 mg microspheres (total dose: 240 mg of microspheres). A maximum dose at which the toxic effects could be irreversible was not observed. n=1. A0 pressure indicates aortic pressure; C, control pair of crystals; EDL, end-diastole length; ESL, end-systole length; HR, heart rate; I, ischemic pair of crystals; LV pressure, left ventricle pressure and its derivative LV dP/dt, left ventricular dP/dt; LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure; Max L, maximum length; Min L, minimum length; SS, systolic shortening.

DOI: 10.1161/JAHA.114.000946

Journal of the American Heart Association
Collagen Deposition

Histological Analysis of Vascular Density and Collagen Deposition

Hearts were cut into 6, 10-mm-thick short-axis transverse ventricular slices, from apex to base. LV, right ventricle, and total heart areas and perimeters, LV cavity diameters, scar length, maximum (Tmax scar) and minimum (Tmin scar) scar thickness, and uninfarcted wall thickness were measured in each photographed infarcted short-axis slice by using Image-Pro plus software (Media Cybernetics, USA), then added and divided by the number of infarcted slices. Myocardial infarct expansion index was calculated as described previously21 (LV cavity area/total heart area) × (uninfarcted septum thickness/infarcted LV free wall thickness). Afterward, slices were embedded in paraffin and 4-μm-thick sections were stained with hematoxylin–eosin, elastic fibers, and Masson-trichrome. Masson-trichrome staining was used for vascular density analysis. Staining of elastic fibers identified that newly generated vessels were arterioles. Arterioles were counted in the whole infarct area using the box-counting method. Total size of necrotic area was calculated by adding single areas of all affected histological sections scanned with Epson perfection v100 photos Scanner (Epson Ltd, Herts, UK) and quantified using Image-Pro plus software. Collagen fiber content and its structure in the scar were qualitatively assessed with picrosirius red staining and polarized light microscopy. Immunohistochemistry was used for analysis of collagen IV content (COL4A2 Antibody [C-17], Santa Cruz Biotechnology, Inc) in the scar, also identifying basement membrane surrounding blood vessels.

Analysis of microRNA Expression

In 3 pigs, 47 mg of ME (3 mg/mL) containing antagomir-92a (0.1 mg/kg body weight) dissolved in 2 injections of 7.8 mL of 0.15 mol/L PBS containing 0.01% Tween 80 were delivered to the LAD. Animals were euthanized at 1, 3, and 10 days after treatment and expression of miR-92a and other endogenous microRNA that served as controls (miR-123, -203, and -126) was quantified in 2 replicate infarcted and control samples by total RNA isolation and real-time quantitative reverse transcription polymerase chain reaction using specific primers. Total RNA was isolated and reverse-transcribed into cDNA using Exiqon kits according to the manufacturer’s protocol. For analysis of microRNA expression in heart samples, we carried out a SYBR® Green–based real-time quantitative reverse transcription polymerase chain reaction (Applied Biosystems) with specific primer sets for amplification (miR-92a, miR-123, miR-203, and miR-126 [Exiqon]). The small RNA molecule U6 small nuclear RNA was amplified as a control.

Statistical Analysis

All statistical analyses were performed with SPSS 15.0. Data are expressed as the mean±SEM. Multiple group comparison was performed by 1-way ANOVA followed by the Bonferroni procedure for comparison of means. The χ² test was used to compare percentages. Pearson’s correlation was used to analyze the degree of linear relationship between vascular density and microcirculatory resistances. Values of P<0.05 were considered statistically significant.

Results

Antagomir-92a Can Be Encapsulated in ME

We first defined the appropriate composition and morphological and granulometric characteristics of the delivery system. Spherical microparticles of biodegradable and biocompatible PLGA polymer were obtained by an emulsion and solvent evaporation method. The inherent viscosity of the polymer ranged from 0.16 to 0.24 dL/g (Figure 1). Taking into account the diameter of the cardiac microvascular network, a 10-μm particle size was considered appropriate to ensure delivery of the ME to the capillaries of the infarcted area while
minimizing the risk of arteriolar obstruction. An adequate particle size distribution with a mean size of 9.04 μm, 82.13% of them between 5 μm and 25 μm and no particles larger than 25 μm, was obtained by the microencapsulation method described above (Figure 2). Loads of 7% to 10% of antagomir-92a were determined by spectrophotometry, with encapsulation efficiency of 74% and preservation of drug integrity.

ME Can Be Selectively Delivered in Reperfused Myocardium

Analysis of heart samples with optical fluorescence microscopy (blue light with wavelength of 495 nm) demonstrated that fluorescently labeled ME were retained in the capillaries of the damaged area (Figure 3).

ME Can Be Safely Delivered in Reperfused Myocardium With No Local or Distant Adverse Effects

Fluorescence was detected exclusively in the anterior myocardial wall (Figure 4), establishing that ME were retained in the heart and few if any entered into circulation.

To investigate the potential myocardial toxicity and the safety range of therapeutic dosage, the 2 injections of 30 mg fluorescently labeled ME (Figures 5 and 6) and 2 progressively higher doses (Figures 7 and 8) in successive injections (120 and 240 mg fluorescently labeled ME, n=2) were administered in the LAD of healthy pigs. Two pairs of piezoelectric crystals were implanted in anterior and posterior myocardium, respectively. Injections caused minor and rapidly reversible depressions of segment shortening in the LAD territory as measured with the piezoelectric crystals. Segment shortening and LAD flow remained stable after the last injection. Triphenyltetrazolium staining and histological analysis failed to show areas of myocardial necrosis. Furthermore, injections caused no arrhythmias.

Encapsulated Antagomir-92a Downregulates miR-92a in a Sustained Manner After Intracoronary Administration

In infarcted tissue, miR-92a expression 1 and 3 days after treatment was downregulated 8- and 2-fold, respectively, in
comparison with control tissue. Inhibition occurred as early as day 1 and was still present at day 10, with expression levels being 5 times lower than in the control area. No significant changes were detected in the other miRs at all time points investigated (Figure 9). These results demonstrate a sustained inhibition of miR-92a with a single intracoronary administration.

**Table 1. Baseline Characteristics of Minipigs**

|                      | Saline (n=9) | Placebo ME (n=9) | Antagogmir-92a ME (n=8) | P Value |
|----------------------|-------------|------------------|-------------------------|---------|
| Age, months          | 12.6±1      | 12.2±0.7         | 12.4±0.8                | 0.96    |
| Male, %              | 100         | 100              | 100                     | —       |
| Weight, kg           | 24.5±1.7    | 27.3±1.8         | 26.8±1.3                | 0.42    |
| Heart rate, beats/min| 82±8        | 73±7             | 86±9                    | 0.49    |
| Blood pressure, mm Hg|             |                  |                         |         |
| Systolic             | 123±6       | 118±6            | 117±8                   | 0.79    |
| Diastolic            | 75±5        | 65±3             | 73±6                    | 0.27    |
| O2 Sat, %            | 97.6±0.8    | 98.2±0.6         | 97.2±1                  | 0.67    |
| CO2, mm Hg           | 38.7±1.6    | 36.2±1.1         | 35.2±1.5                | 0.25    |
| Temperature, °C      | 36.3±0.4    | 36.5±0.3         | 36.7±0.4                | 0.74    |
| Hematocrit, %        | 30.5±1.5    | 28.7±1.7         | 28.4±1.6                | 0.61    |
| Creatinine, mg/dL    | 0.78±0.03   | 0.77±0.05        | 0.79±0.03               | 0.93    |
| LAD size*, n (%)     |             |                  |                         | 0.46    |
| Small                | 2 (22.2)    | 0 (0)            | 1 (12.5)                |         |
| Medium               | 3 (33.3)    | 2 (22.2)         | 1 (12.5)                |         |
| Large                | 1 (11.1)    | 5 (55.6)         | 3 (37.5)                |         |
| Very large           | 3 (33.3)    | 2 (22.2)         | 3 (37.5)                |         |

Data are means±SEM. n=26. CO2 indicates partial pressure of end-tidal carbon dioxide (capnography); LAD, left anterior descending coronary artery; ME, microspheres; O2 Sat, oxygen saturation; LAD size* small, LAD that does not reach the apex; medium, reaches the apex but without turning; large, supplies all the apex; LAD that is very large, LAD which irrigates part of the posterior septum).

**Table 2. Contractility of Left Ventricle**

|                      | Saline (n=9) | Placebo ME (n=9) | Antagogmir-92a ME (n=8) | P Value |
|----------------------|-------------|------------------|-------------------------|---------|
| LVEF MOD A4C, % baseline | 72.6±9.2    | 71.9±8.5         | 68.1±5.9                | 0.52    |
| CO MOD A4C, L/min baseline | 2.3±0.2    | 1.9±0.3          | 1.6±0.3                 | 0.22    |
| LVEF MOD A4C, % after AMI | 47.9±4     | 52.3±4.8         | 51.7±3.4                | 0.72    |
| CO MOD A4C, L/min after AMI | 1.8±0.2   | 1.8±0.4          | 1.7±0.2                 | 0.92    |
| LVEF MOD A4C, % reperfusion | 56.4±3.4  | 53.4±4.5         | 59.1±3.5                | 0.6     |
| CO MOD A4C, L/min reperfusion | 1.6±0.2   | 1.4±0.2          | 2±0.6                   | 0.49    |
| LVEF MOD A4C, % at 1-month fup | 36.7±3.3  | 46.4±5.3         | 51.4±5.7                | 0.15    |
| ATVEF MOD A4C, % | –30±4.7     | –16.4±3.9        | –14.3±6.9               | 0.15    |
| ATCO MOD A4C, L/min | –0.22±0.43  | –0.21±0.36       | 0.63±0.4                | 0.2     |

Data are expressed as means±SEM. Contractility of left ventricle measured by intravascular echocardiography. A4C indicates 4 chambers view; AMI, acute myocardial infarction; CO MOD A4C indicates cardiac output; fup, follow-up; LVEF MOD A4C, left ventricular ejection fraction; ME, microspheres; MOD, method of disc.

Downregulation of miR-92a Induces Cardiac Neoangiogenesis and Reduces Microcirculatory Resistance in the Infarcted Area

In the next series of experiments, we investigated whether inhibition of miR-92a by intracoronary injection of encapsulated antagomir-92a leads to enhancement of angiogenesis in the...
infarcted area. In this phase, 27 adult minipigs were allocated to receive saline, placebo ME, or antagomir-92a-containing ME (0.1 mg/kg body weight) by intracoronary administration at 5 minutes reperfusion after AMI (Figure 10). Four weeks later, functional studies were performed and hearts were obtained. Baseline characteristics (Table 1) and baseline LV contractility were similar in all groups (Table 2), and no differences were observed in left ventricular ejection fraction (Table 2) or in troponin I levels measured at the last minute of balloon occlusion (Table 3). At reperfusion, LAD flow grade by the Thrombolysis in Myocardial Infarction Study Group (TIMI) criteria (Table 4) and LV contractility (Table 2) were also homogeneous. No differences were observed in growth and vital parameters between groups at follow-up (Table 5). Four weeks after treatment, the baseline MR and the true microcirculatory resistance (TMR) were consistently lower in treated animals than in controls (7.47±1.33 versus 19.62±2.98, P=0.005 and 5.0±1.15 versus 14.49±2.4, P=0.006, respectively) (Figure 11). Histopathological analysis demonstrated significantly higher vascular density in the necrotic area in those animals receiving encapsulated antagomir-92a compared with controls (161.57±58.71 versus 68.49±23.56 in placebo group versus 73.91±24.97 in saline group, P=0.001) (Figure 12A, 12B, 12C, and 12D) and it significantly correlated with both baseline MR and TMR (r=0.59, P=0.03 and r=0.56, P=0.047, respectively) (Figure 12E and 12F). Microvascularity increased within both the infarct zone and the peri-infarct rim. Taken together, these data indicate that encapsulated antagomir-92a induces angiogenesis that is detectable 1 month after AMI.

Encapsulated Antagomir-92a Prevents Left Remodeling

Bellera et al

Table 3. Cardiac Enzymes

|                | Saline (n=9) | Placebo ME (n=9) | Antagomir-92a ME (n=8) | P Value |
|----------------|-------------|------------------|------------------------|---------|
| Trop I baseline, ng/mL (n=26) | 0.03±0.006   | 0.02±0.004       | 0.02±0.009             | 0.32    |
| Trop I after AMI, ng/mL (n=26) | 0.4±0.13     | 0.3±0.07         | 0.2±0.06               | 0.16    |
| Trop I 6 h, ng/mL (n=22)      | >10          | >10              | >10                    | —       |

Trop I at baseline, after AMI induction (at last minute of AMI induction) and 6 hours after the onset of coronary occlusion were measured by Triage MeterPro™, using the Kit Trop I New Generation (Alere™, Izasa Werfen Group). Plus-minus values are means±SEM. AMI indicates acute myocardial infarction; ME, microspheres; Trop I, troponin I.

Encapsulated Antagomir-92a Induces Favorable Healing and Prevents Adverse Remodeling

To determine the effects of encapsulated antagomir-92a on ventricular remodeling, we compared functional parameters

Table 4. TIMI Flow Score in LAD

|                | Saline (n=9) | Placebo ME (n=9) | Antagomir-92a ME (n=8) | P Value |
|----------------|-------------|------------------|------------------------|---------|
| Baseline (n=26)|             |                  |                        |         |
| TIMI evaluation, n n=9 | n=9 | n=8 | — |       |
| 3, n (%)       | 9 (100%)    | 9 (100%)         | 8 (100%)               |         |

After AMI and treatment (n=26)

|                | Saline (n=9) | Placebo ME (n=9) | Antagomir-92a ME (n=8) | P Value |
|----------------|-------------|------------------|------------------------|---------|
| TIMI evaluation, n n=9 | n=9 | n=8 | — | 0.52 |
| 1, n (%)       | 1 (11.1)    | 0                | 0                      |         |
| 2, n (%)       | 2 (22.2)    | 2 (22.2)         | 4 (50)                 |         |
| 3, n (%)       | 6 (66.7)    | 6 (66.7)         | 3 (37.5)               |         |
| Not assessable*, n (%) | 0 | 1 (11.1) | 1 (12.5) |         |

1 month after AMI (n=20)

|                | Saline (n=9) | Placebo ME (n=9) | Antagomir-92a ME (n=8) | P Value |
|----------------|-------------|------------------|------------------------|---------|
| TIMI evaluation, n n=6 | n=7 | n=7 | 0.57 |
| 0, n (%)       | 1 (16.7)    | 1 (14.3)         | 0                      |         |
| 1, n (%)       | 0           | 0                | 0                      |         |
| 2, n (%)       | 0           | 0                | 1 (14.3)               |         |
| 3, n (%)       | 5 (83.3)    | 6 (85.7)         | 6 (85.7)               |         |

TIMI flow in LAD was evaluated as previously described19 and registered at baseline, just after reperfusion and treatment completion, and at 1-month follow-up. AMI indicates acute myocardial infarction; LAD, left anterior descending coronary artery; ME, microspheres; TIMI, Thrombolysis In Myocardial Infarction flow grade.

*TIMI flow was not asessable in 2 cases after AMI, because of shock and severe hypotension. No differences were observed among the 3 groups.
by IVE and morphological and structural parameters in the antagomir-treated and nontreated groups by ex vivo cardiac magnetic resonance imaging and in short-axis transverse ventricular histological slices. A significantly higher percentage of control animals with septoapical dyskinesia was identified by IVE (76.9 versus 28.6%, \( P<0.03 \)) (Figure 13A and 13B). A strong tendency toward a better left ventricular ejection fraction in the treated group was observed (51.4±5.7 versus 36.7±3.3 versus 46.4±5.3, \( P=0.15 \)) (Table 2). The percentages of injured ventricular wall thinning adjusted for the normal wall thickness, adverse remodeling-mediated morphological changes in the LV in CMR, and the myocardial infarct expansion index in histological slices were also significantly higher in controls than in treated animals (Figure 14 and Tables 6 and 7). These findings suggest a protective effect of antagomir-92a toward cardiac remodeling after AMI that can be attributed to angiogenesis.

### Favorable Healing Is Associated With the Major Proportion of Mature Collagen

Qualitative differences between the 2 treatment groups in fibrillar hue content, alignment and spatial distribution of collagen in scars were observed. Multidirectional cross-linked thick orange and red fibers were the dominant collagen structures in treated animals, whereas longitudinally aligned parallel thin green collagen fibers were exclusively detected in nontreated scars (Figure 15). Collagen IV was identified mainly in the peripheral zone and less in the center of the scar. No qualitative differences were observed between groups of the scars (Figure 16).

### Intracoronary Injection of Encapsulated Antagomir-92a in Reperfused Myocardium Is Not Associated With Adverse Effects

Malignant arrhythmias during ischemia or at reperfusion were frequent, requiring defibrillation, with no differences between groups (Table 8). No antiarrhythmic drugs were administered. An extra 3-mL bolus of fentanyl was administered in cases of recurrent, nonsustained ventricular arrhythmias or repeated defibrillation, with no differences between groups in total

---

**Table 5. Characteristics of the Minipigs at 1-Month Follow-Up**

|                  | Saline (n=6) | Placebo ME (n=7) | Antagomir-92a ME (n=7) | \( P \) Value |
|------------------|-------------|-----------------|-----------------------|--------------|
| Age, months      | 14.2±1.4    | 14.1±0.7        | 13.9±0.8              | 0.97         |
| Weight, kg       | 25.8±3.4    | 28.4±3.3        | 27.1±2                | 0.82         |
| \( \Delta \) Weight at 1 month, kg | 0.7±1.9     | 0.5±1.3         | –0.7±1.6              | 0.81         |
| Heart weight, g  | 149.6±7.1   | 152±9.8         | 157.1±15.6            | 0.9          |
| Heart rate, beats/min | 100±14.3   | 84±8            | 75±3.7                | 0.18         |
| Blood pressure, mm Hg |           |                 |                       |              |
| Systolic         | 96±9.8      | 119±8.1         | 119±7.1               | 0.12         |
| Diastolic        | 58±7        | 69±5.6          | 68±6.2                | 0.43         |
| \( O_2 \) Sat, % | 98.2±0.7    | 97.9±0.6        | 97.4±1                | 0.81         |
| \( CO_2 \), mm Hg| 35.2±1.9    | 36.8±2.3        | 35.1±1.8              | 0.78         |
| Temperature, °C  | 36.7±0.09   | 35.9±0.42       | 36.7±0.6              | 0.45         |
| Hematocrit, %    | 22.9±0.97   | 24.8±1.15       | 25.4±2.16             | 0.56         |
| Creatinine, mg/dL| 0.74±0.09   | 0.77±0.07       | 0.79±0.05             | 0.87         |

Vital parameters were measured at the same moment in all animals, when the femoral arterial sheath was placed and blood pressure start to being monitored. Plus-minus values are means±SEM. \( n=20 \). \( CO_2 \) indicates partial pressure of end-tidal carbon dioxide (capnography); ME, microspheres; \( O_2 \) Sat, oxygen saturation.

---

**Figure 11.** Baseline (baseline MR) and true microcirculatory resistance (TMR) measured 1 month after AMI in the infarct-related artery of minipigs treated and nontreated with encapsulated antagomir-92a. The baseline MR was significantly lower in the treated group compared with controls (7.47±1.33 vs 19.62±2.98, \( *P=0.005 \)), \( n=13 \). Significantly lower TMR (hyp) was observed in the treated group compared to controls (5.0±1.15 vs 14.49±2.4, \( **P=0.006 \)), \( n=13 \). AMI indicates acute myocardial infarction; ME, microspheres; MR, microcirculatory resistance.
administered dose ($P=0.68$). Moreover, to further address this issue, an insertable loop recorder was randomly implanted in 10 of the study’s 27 minipigs to detect potential episodes of arrhythmia until sacrifice at 1 month postinfarction and treatment. Malignant tachyarrhythmias or clinically relevant bradyarrhythmias were not observed in either treated or control groups, indicating that intracoronary encapsulated antagomir-92a has no proarrhythmic effect (Table 8). Mortality during or directly after the procedure was 15%. Global study mortality was 23% (Table 9). No differences were observed in short-term mortality between groups. No vascular tumors were observed in any of the animals upon necropsy analysis, consistent with the absence of ectopic systemic suppression of microRNA-92a in other, remote organs.

**Discussion**

Our investigation provides evidence of an effective, vectorized antagomir therapy that induces favorable posts ischemic myocardial repair. We have demonstrated that a local intracoronary delivery system based on microencapsulation avoids systemic antagomir-92a biodistribution, allows local, sustained miR-92a inhibition and neovasculogenesis, and prevents adverse ventricular remodeling.

Adverse ventricular remodeling is presently still the major cause of contractile dysfunction and heart failure after an AMI. Despite advances in pharmacological treatments, reperfusion, resynchronization, and cell therapy, its occurrence has not been abolished. The thinning and expansion of the infarct area, which results in ventricular dilatation, has been associated with a worsened state of the microcirculation. Consequently, improving the vascular network by induction of neoangiogenesis has already been proposed as a way to prevent adverse ventricular remodeling. Although benefits have been observed in preclinical experiments with proangiogenic factors, little if any effect has been observed thus far in clinical trials. Antagomir-92a has been described to be cardioprotective and to induce neovascularization in
small- and large-animal models, but its beneficial effect against adverse postinfarction remodeling was unknown.\textsuperscript{13,14} In our study, in a clinically relevant adult minipig model of AMI with transient coronary occlusion and reperfusion, microencapsulated antagomir-92a induced growth of vessels in the infarcted area and led to a significantly reduced occurrence of adverse ventricular remodeling. This model rules out that the observed biological effects are mediated by pathways or stimuli activated only during the growth period of an animal’s life. The underlying mechanism by which induction of neoangiogenesis prevents

![Image](https://example.com/image1)

**Figure 13.** Analysis of regional wall motion dysfunction by intravascular echocardiography (IVE). A, Representative 2-dimensional images showing the apex of the left ventricle, septum, and mitral valve obtained at baseline, just at the end of ischemia, and at 1 month after AMI are shown. B, One month after AMI, the presence of septoapical dyskinesia was evaluated by an echocardiographer blind to the allocated treatment. The percentage of animals with septoapical dyskinesia in treated and nontreated animals is shown (28.6% vs 76.9%, *P*<0.05). *n*=20. AMI indicates acute myocardial infarction; fup, follow-up; ME, microspheres.

![Image](https://example.com/image2)

**Figure 14.** Representative trichrome-stained short-axis ventricular sections showing the infarct area of 3 minipigs of the study allocated to each group of treatment. The favorable healing observed in the encapsulated antagomir-92a treated group is shown. *P*>0.05 necrotic area of treated group versus untreated. ME indicates microspheres.
### Table 6. Parameters of Left Ventricular Remodeling in CMR

|                          | Saline (n=6) | Placebo ME (n=5) | Antagomir-92a ME (n=6) | P Value |
|--------------------------|-------------|------------------|------------------------|---------|
| No. of infarcted slices  | 4.8±0.3     | 4.8±0.4          | 5.3±0.2                | 0.38    |
| \(T_{\text{max}}\) infarcted wall, mm | 6.07±0.9   | 5.61±0.5         | 9.01±0.6               | <0.0001 |
| \(T_{\text{min}}\) infarcted wall, mm | 3.17±0.4   | 4.02±0.9         | 4.35±0.5               | 0.33    |
| \(T_{\text{normal}}\) posterior wall, mm | 13.23±0.5  | 13.32±1.8        | 11.82±0.7              | 0.49    |
| Perc. of minimum thinning, % | 54.79±4.9  | 56.74±4.1        | 22.71±5.5              | <0.0001 |
| Perc. of maximum thinning, % | 76.40±2.18 | 69.86±4.72       | 62.54±4.19             | 0.05    |
| Length of the thinning infarcted wall, mm | 32.2±1.8   | 31.7±4           | 20.5±3.6               | 0.03    |
| LV DN, mm                | 14.88±0.68  | 13.78±1.59       | 17.5±1.37              | 0.12    |
| LV DR/DN                 | 1.93±0.2    | 2.02±0.2         | 1.29±0.1               | 0.03    |
| Adverse remodeling, % (n) | 83.3 (5)    | 80 (4)           | 16.7 (1)               | 0.03    |

Data are expressed as means±SEM. CMR indicates cardiac magnetic resonance; LV, left ventricle; LV DN, maximum diameter between normal ventricular walls; LV DR, maximum diameter between remodeled and contralateral normal wall; LV DR/DN, sphericity index; ME, microspheres; No., number; Perc., percentage; \(T_{\text{max}}\) infarcted wall, maximum infarcted wall thickness; \(T_{\text{min}}\), minimum infarcted wall thickness; \(T_{\text{normal}}\) posterior wall, noninfarcted wall thickness.

### Table 7. Parameters of Left Ventricular Remodeling Analyzed in Short-Axis Transverse Ventricular Histological Slices

|                          | Saline (n=6) | Placebo ME (n=7) | Antagomir-92a ME (n=7) | P Value |
|--------------------------|-------------|------------------|------------------------|---------|
| No. of infarcted slices  | 2.5±0.22    | 2.83±0.17        | 2.71±0.18              | 0.5     |
| Areas                    |             |                  |                        |         |
| LV cavity area, cm²      | 4.93±0.48   | 5.03±0.75        | 3.59±0.38              | 0.13    |
| RV cavity area, cm²      | 3.66±0.76   | 4.51±0.81        | 2.96±0.44              | 0.28    |
| Total heart area, cm²    | 22.83±1.48  | 25.43±2.51       | 21.53±1.48             | 0.34    |
| LV ext area, cm²         | 15.22±1.16  | 17.81±1.8        | 14.31±1.33             | 0.23    |
| RV ext area, cm²         | 6.19±1.04   | 7.22±1.12        | 5.58±0.73              | 0.49    |
| Perimeters               |             |                  |                        |         |
| LV perimeter, cm         | 10.27±0.44  | 9.9±0.72         | 9.18±0.27              | 0.29    |
| RV perimeter, cm         | 10.18±0.92  | 10.36±0.93       | 9.04±0.66              | 0.47    |
| Total heart perimeter, cm| 17.40±0.53  | 18.13±0.95       | 16.66±0.64             | 0.36    |
| LV ext perimeter, cm     | 13.56±2.68  | 14.88±1.05       | 12.55±1.11             | 0.33    |
| RV ext perimeter, cm     | 13.22±1.24  | 13.64±0.97       | 11.86±1.04             | 0.48    |
| Diameters                |             |                  |                        |         |
| LV D_{\text{max}}, cm   | 3.26±0.48   | 3.23±0.23        | 2.71±0.09              | 0.06    |
| LV D_{\text{min}}, cm   | 1.61±0.05   | 1.59±0.21        | 1.61±0.1               | 0.99    |
| LV D_{N}, cm             | 3.16±0.21   | 3.19±0.22        | 2.35±0.08              | 0.004   |
| LV D_{N}, cm             | 1.64±0.06   | 1.71±0.22        | 1.93±0.19              | 0.47    |
| LV D_{N}/D_{N}           | 1.95±0.14   | 2.04±0.28        | 1.29±0.13              | 0.024   |
| Myocardial infarct expansion index | 6.75±1.19  | 6.56±0.64        | 2.8±0.31               | 0.006   |
| Scar lengths             |             |                  |                        |         |
| \(T_{\text{max}}\) scar, cm | 0.52±0.12  | 0.4±0.03         | 0.68±0.07              | 0.04    |
| \(T_{\text{min}}\) scar, cm | 0.32±0.08  | 0.23±0.02        | 0.39±0.04              | 0.121   |
| Scar length, cm          | 3.42±0.28   | 3.21±0.20        | 3.06±0.13              | 0.53    |

Data are expressed as means±SEM. ext indicates external; LV, left ventricle; LV D_{\text{max}}, maximum LV diameter; LV D_{\text{min}}, minimum LV diameter; LV D_{N}, maximum diameter between normal ventricular walls, perpendicular to D_{N} and passing nearest the center of the ventricular cavity; LV D_{N}', maximum diameter between remodeled and contralateral normal wall, passing through the cavity center; ME, microspheres; No., number; RV, right ventricle; \(T_{\text{max}}\) scar, maximum scar thickness; \(T_{\text{min}}\) scar, minimum scar thickness.
adverse remodeling has been previously investigated. Prevention of cell death of hypertrophied viable myocytes and modification of collagen deposition and scar formation after neoangiogenesis have been demonstrated in a rodent model of myocardial infarction.\(^2\) Accordingly, in our study, the scar of treated animals differed qualitatively from that of controls in the

Figure 15. Qualitative assessment of myocardial collagen composition and structural organization by polarized light analysis of picrosirius red–stained histological sections. A different qualitative composition of collagen fibers was observed in scars of treated vs nontreated animals. The cross-linked structure of mature collagen triple helix was exclusively observed in treated animals scars (A through C), showing reddish color with picrosirius red and polarized light microscopy. However, scars of nontreated animals were mainly composed of immature collagen with longitudinal nonlinked fibers with green refringence (D through F). Moreover, whereas in control animal scars the collagen fibers exhibit a longitudinal layout, swirling and multidirectional fibers was the most abundant disposition in treated scars.

Figure 16. Qualitative assessment of deposition of nonfibrillar collagen IV in the scar at 1 month after AMI. Immunohistochemistry was used to analyze collagen IV content (COL4A2 Antibody [C-17], Santa Cruz Biotech) in the scar, also identifying basement membrane surrounding blood vessels. A, Representative section of peripheral infarct tissue of an animal treated with antagomir-92a. Collagen IV content and arterioles are shown (brown coloration). B, Representative section of peripheral infarct tissue of a control animal. Qualitatively, similar collagen IV deposition was observed in treated and nontreated animals. AMI indicates acute myocardial infarction.
collagen composition, with a higher proportion of mature cross-linked collagen I fibers. This higher proportion of collagen I and its multidirectional spatial distribution could determine the major stiffness and mechanical strength of the repair tissue and could have contributed to preventing adverse postinfarct remodeling.39,40 While collagen I and III are the most abundant collagens in the reparative scar, recent studies suggest that the nonfibrillar collagens are also deposited during pathological postinfarct healing.41,42 Collagen IV content was detected in the infarct tissue in our study, which could reinforce its role in the organization of the fibrillar collagen network. However, a qualitatively similar proportion of collagen IV deposition was observed in treated and nontreated animals. The influence of the new vessels on cardiac fibroblast activation and fibrillar and nonfibrillar collagen deposition during the healing process requires future investigation.

Several obstacles prevent the translation of intravenous injections of antagomir-92a to the prevention of adverse remodeling in clinical practice. Since the polycistronic microRNA 17-92a cluster is ubiquitously expressed, nonselective cell penetration and diffuse miR-92a inhibition in noncardiac organs observed with systemic and regional application may cause unwanted adverse effects at remote locations.14 In addition, to obtain an adequate and sustained concentration in the target cells, antagomir-92a must be repeatedly injected, which increases total doses, risks, and costs.13,14 Moreover, the role of the cluster-17-92 in carcinogenesis, tumoral vasculogenesis, and invasiveness has been previously shown, which raises concerns about the safety of nonvectorized administration of antagomirs of this cluster.16,17,43–45 To circumvent these obstacles, different drug delivery systems are being investigated. Liposomes and nanoparticles have been developed and used in vivo, but their use has not avoided the potential problems associated with systemic delivery of microRNAs.46,47 Bioengineered non-pathogenic viruses with affinity for the myocardium have also been used, but biodistribution and incomplete affinity for the myocardium requires higher dosage.48,49 Moreover, no study

| Table 8. Arrhythmias Detected During the Study |
|-----------------------------------------------|
|                                              |
| Ischemic phase (n=26)                         |
|                                               |
| No arrhythmias, n (%)                         |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| Arrhythmias, n (%)                           |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| PVC, n                                        |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| NSVT, n                                       |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| Ventricular fibrillation, n                   |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| Reperfusion phase (n=26)                      |
|                                               |
| No arrhythmias, n (%)                         |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| Arrhythmias, n (%)                           |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| PVC, n                                        |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| NSVT, n                                       |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| During 30 days after AMI (n=10)               |
|                                               |
| Implantable loop recorder                     |
| n=4                                          |
| n=3                                          |
| n=3                                          |
| P Value                                       |
|                                               |
| No arrhythmias, n (%)                         |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| Arrhythmias, n (%)                           |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| PVC, n                                        |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |
| NSVT, n                                       |
| Saline (n=9)                                  |
| Placebo ME (n=9)                              |
| Antagomir-92a ME (n=8)                        |
| P Value                                       |
|                                               |

AMI indicates acute myocardial infarction; IVR, idioventricular rhythm; ME, microspheres; NSVT, nonsustained ventricular tachycardia; PVC, premature ventricular complexes; PSVC, premature supraventricular complexes.

*Data at 1 month could not be assessed in 2 animals assigned to the saline group; in 1 the device self-explanted accidentally and the other died in the operating room just after its insertion.
has demonstrated the efficacy and safety of percutaneous intracoronary administration of these delivery vectors without previous aortic clamp. To overcome this hurdle, we devised a suitable vehicle for safe intracoronary administration of an antagomir using ME designed with a biocompatible and bioabsorbable polymer. We demonstrated that ME are retained exclusively in the infarct zone. Therefore, the microencapsulated antagomir-92a can be delivered directly to the target tissue, allowing sustained release during biodegradation of the particle coating. The dose of antagomir-92a used in our study (0.1 mg/kg body weight) was fully effective in blocking miR-92a. A previous study in pigs showed efficacy with local heart delivery of 0.03 mg antagomir-92a/kg body weight. The minimal dose of the microencapsulated antagomir capable of suppressing miR-92a needs to be determined in further studies. A single intracoronary administration downregulated miR-92a at least 10 days after treatment, which suggests that the disadvantages of repeated injections for up to 7 days after suffering an AMI could be avoided. Thus, this novel strategy of encapsulation and local action with low total dose and without local or systemic toxicity offers opportunities for the therapeutic application of genetic regulators in a wide range of cardiovascular disorders.

In our experiments, the sustained inhibition of miR-92a in the infarcted tissue induced neoangiogenesis, consistent with previous observations. Ours is the first study that directly demonstrates significantly lower microvascular resistance in the infarct tissue and retention of the response to adenosine, reflecting functionality of the newly generated vessels at 1 month of follow-up.

Intracoronary injection of ME may cause capillary or arteriolar occlusion, depending of the size and number of the particles, and can cause myocardial ischemic injury. However, ME are used to measure regional myocardial blood flow in large animals, and it is known that with appropriate doses and particle size no significant effects are observed after repeated injections. In fact, we did not observe any significant local adverse effects after multiple injections of ME into healthy myocardium. Moreover, injection of ME should be expected to be even safer when performed on necrotic myocardium.

Finally, our study mortality was similar to that reported in previous experimental AMI studies, without differences between treated and nontreated groups. Of 6 pigs that died, 4 died during AMI induction from causes not related to outcomes: 2 because of technical problems in the surgical preparation and 2 due to arrhythmias. To the best of our knowledge, no relationship has been demonstrated between arrhythmias during the acute phase of ischemia-reperfusion and adverse ventricular remodeling. One of these 2 animals with arrhythmic death during the acute phase was in the saline group. We cannot rule out that the 2 pigs that died after

| Table 9. Study Mortality |
|--------------------------|
|                         | Saline (n=9) | Placebo ME (n=9) | Antagomir-92a ME (n=8) | P Value |
| Periprocedural mortality*, n (4 of 26: 15.4%) | 2 | 2 | 0 | 0.35 |
| Causes of mortality, n | | | | |
| Cardiogenic shock due to severe left ventricular dysfunction secondary to thrombus in left main emboled from catheter during TIMI flow analysis at reperfusion | 1 | | | |
| Arrhythmic storm | | 1 | | |
| Retroperitoneal hemorrhage | | | 1 | |
| Bradycardia and asystole | | | 1 | |
| Mortality 30 days after AMI, n (2 of 22: 9.1%) | 1 | 0 | 1 | 0.59 |
| Causes of mortality, n | | | | |
| Sudden death (probably arrhythmia. No signs of heart failure were observed in necropsy) | 1 | | | |
| Heart failure | | | 1 | |
| Global mortality, n (6 of 26: 23%) | 3 | 2 | 1 | 0.59 |

AMI indicates acute myocardial infarction; ME, microspheres; TIMI, Thrombolysis In Myocardial Infarction flow grade.

*Periprocedural mortality: occurring during or soon (<6 hours) after the performance of the AMI procedure.
Capsulated Antagomir-92a Prevents Left Remodeling

Bellera et al.

the ischemia–reperfusion procedure had larger infarcts and/or more adverse ventricular remodeling, but they were equally distributed between the control and the encapsulated antagomir-92a group. Therefore, we do not think that our analysis may have been biased because loss of data.

In summary, this study shows that a single intracoronary administration of encapsulated antagomir-92a at the time of reperfusion can stimulate neangiogenesis in the infarct tissue and prevent adverse ventricular postinfarction remodeling in a clinically relevant model of myocardial infarction without evidence of systemic effects. This new therapeutic approach could be useful in patients with AMI treated with emergent percutaneous coronary intervention and at risk of adverse ventricular remodeling.

Sources of Funding

This work was funded by the Spanish Ministry of Science (SAF 2008/03067) and Carlos III Institute of Health (Cardiovascular Research Network RD12/0042/0021, project grants PI12/00788 and PI12/01738 to Garcia-Dorado, and supported by grants from the Spanish Society of Cardiology and Ullysses 2011 prize to Bellera. Barba is a recipient of a Ramón y Cajal Fellowship.

Disclosures

Garcia-Dorado, Bellera, Barba, Rodriguez-Sinovas, Pérez, Ferret, and Asín hold a patent for microencapsulated antagomir-92a. The remaining authors report no conflicts of interest.

References

1. Savoye C, Equine O, Tricot O, Nugue O, Segrestin B, Sauti E, Karam J, Ulysses 2011 prize to Bellera. Barba is a recipient of a Ramón y Cajal Fellowship. DOI: 10.1161/JAHA.114.000946

2. Garcia-Dorado, Bellera, Barba, Rodriguez-Sinovas, P., Ulysses 2011 prize to Bellera. Barba is a recipient of a Ramón y Cajal Fellowship. DOI: 10.1161/JAHA.114.000946

3. Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y, Della Siega A, Bilodeau L, Burton JR, Proulx G, Radhakrishnan S, NORTHERN Trial Investigators. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting onco-gene-induced senescence. Circ Res. 2010;108:3068–3071.

4. Stengvar J, Kauppinen S, MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther. 2008;8:59–81.

5. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takashima T, Zeher AM, Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:170–1713.

6. Hinkelman RS, Chen R, Zinman L, Zeher AM, Dimmeler S. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128:1066–1075.

7. Kojima H, Sun GC. Role of microRNAs in the reperfused myocardium towards post-infarct remodeling. Circ Res. 2012;98:284–292.

8. Bonauer A, Carmona G, Iwaseki M, Mione K, Koyanagi M, Fischer A, Burchfield J, Foehle L, ODonohue J, Ou Y, Tang B, Herath M, Villar AS, Zeher AM, Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:170–1713.

9. Hinkelman RS, Chen R, Zinman L, Zeher AM, Dimmeler S. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128:1066–1075.

10. Stengvar J, Kauppinen S, MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther. 2008;8:59–81.

11. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takashima T, Zeher AM, Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:170–1713.

12. Hinkelman RS, Chen R, Zinman L, Zeher AM, Dimmeler S. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128:1066–1075.

13. Stengvar J, Kauppinen S, MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther. 2008;8:59–81.

14. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takashima T, Zeher AM, Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:170–1713.

15. Hinkelman RS, Chen R, Zinman L, Zeher AM, Dimmeler S. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128:1066–1075.

16. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takashima T, Zeher AM, Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:170–1713.

17. Hinkelman RS, Chen R, Zinman L, Zeher AM, Dimmeler S. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128:1066–1075.

18. Garcia-Dorado D, Théroux P, Elizaga J, Galñanes M, Solares J, Riesgo M, Gomez MJ, Garcia-Dorado D, Fernandez-Anxas F, Myocardial reperfusion in the pig heart model: infarct size and duration of coronary occlusion. Cardiovasc Res. 1987;21:537–544.

19. Hackworth RA, Sorensen SG, Fitzpatrick PG, Barry WH, Menlove RL, Rothbard RL, Anderson JL. Dependence of assessment of coronary artery reperfusion during acute myocardial infarction on angiographic criteria and interobserver variability. Am J Cardiol. 1988;62:538–542.

20. Fearon WF, Balsam LB, Farouque HM, Caffarelli AD, Robbins BC, Fitzgerald PJ, Yock PG, Yeung AC. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003;107:3129–3132.

21. Hochman JS, Chou H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation. 1987;75:299–306.

22. Kowalik P, Schulz R, Guth BD, Schade A, Paffhausen W, Gross R, Heusch G. Measurement of regional myocardial blood flow with multiple colored microspheres. Circulation. 1991;83:974–982.

23. Rodriguez-Sinovas A, Bis J, Anivarro I, de la Torre J, Bayés-Genís A, Cinca J. Coronary smooth muscle reactivity to mucinichic stimulation after ischemia-reperfusion in porcine myocardial infarction. J Appl Physiol. 2003;95:81–88.

24. Kirkpatrick JM, Jr, John Sutton M. Assessment of ventricular remodeling in heart failure clinical trials. Circ Heart Fail Rep. 2012;9:328–336.

25. Parodi G, Antonucci D. Left ventricular remodeling after primary percutaneous coronary intervention. Am Heart J. 2010;160:S15–S16.

26. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postfibrination. Am J Cardiol. 2000;86:276–281.

27. Thirouin J, Karam S, Fauconnier J, Roberge S, Cassan C, Cazotta O, Almond F, Lacaze-Campagne A, Babuty D, Richard S. Functional evidence for an active role of B-type natriuretic peptide in cardiomyocyte remodelling and pro-arrhythogenicity. Cardiovasc Res. 2012;95:58–66.

28. Yu H, Zhao G, Li H, Liu X, Wang S, Candesanat antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. Gene. 2012;497:301–306.

DOI: 10.1161/JAHA.114.002096

Journal of the American Heart Association
Encapsulated Antagomir92a Prevents Left Remodeling  
Bellera et al

29. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.

30. Carluccio E, Biagioli P, Alunni G, Murrone A, Pantano P, Biscottini E, Zuchi C, Zingarini G, Cavallini C, Ambrosio G. Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dysynchrony. JACC Cardiovasc Imaging. 2011;4:1067–1076.

31. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705.

32. Kühn B, del Monte F, Hajjar RJ, Chang YS, Lebecche D, Arab S, Keating MT. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med. 2007;13:962–969.

33. Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling. Nature. 2002;415:240–243.

34. Ørn S, Mankenhe C, Greve OJ, Larsen Al, Bonarjee VV, Edvardsen T, Dickstein K. Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. Eur Heart J. 2009;30:1978–1985.

35. Weir RA, Murphy D, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705.

36. Lombardo A, Niccoli G, Natale L, Bernardini A, Cosentino N, Bonomo L, Crea F. Microvascular obstruction remains a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. Eur Heart J. 2010;31:360–367.

37. Lombardo A, Niccoli G, Natale L, Bernardini A, Cosentino N, Bonomo L, Crea F. Impact of microvascular obstruction and infarct size on left ventricular remodeling in reperfused myocardial infarction: a contrast-enhanced cardiac magnetic resonance imaging study. Int J Cardiovasc Imaging. 2012;28:835–842.

38. Ohtsuka M, Takano H, Zou Y, Toko H, Akazawa H, Qin Y, Suzuki M, Hasegawa H, Nakaya H, Komuro I. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J. 2004;18:851–853.

39. Fish JE, Srivastava D. MicroRNAs: opening a new vein in angiogenesis research. Sci Signal. 2009;2:pe1.

40. Badenhorst D, Maseko M, Tsotetsi OJ, Naiddoo A, Brookbank R, Norton GR, Woodiassi AJ. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc Res. 2003;57:632–641.

41. Luther DJ, Thodeti CK, Shamharte PE, Adapala RK, Hodnichak C, Weirhauch D, Bonald P, Chilian WM, Meszaros JG. Absence of type VI collagen paradoxically improves cardiac function, structure, and remodeling after myocardial infarction. Circ Res. 2012;110:851–856.

42. Shamharte PE, Meszaros JG. Non-fibrillar collagens: key mediators of post-infarction cardiac remodeling? J Mol Cell Cardiol. 2010;48:530–537.

43. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109:4399–4405.

44. Dewis M, Horayoun A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38:1060–1065.

45. He L, Thomson JM, Hermann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature. 2005;438:823–833.

46. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP. ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res. 2005;22:2115–2120.

47. Hood JD, Bednarski M, Frausto R, Cordon-Cardo S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404–2407.

48. Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z, Doi H, Matsumoto S, Kondo N, Iida M, Tornai G, Tanaka F, Muramatsu S, Sobue G. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med. 2012;18:1136–1141.

49. Barr E, Carroll J, Kalynych AM, Tripathy SK, Kozarsky K, Wilson JM, Leiden JM. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther. 1994;1:51–58.

50. Iwatake M, Gu Y, Dieterle T, Iwanaga Y, Peterson KL, Hoshijima M, Chien KR, Ross J. In vivo high-efficiency transcoronary gene delivery and Cre–LoxP gene switching in the adult mouse heart. Gene Ther. 2003;10:1814–1820.